We are live on ! Find out more
IRD

Opus Genetics
IRD

30 hedge funds and large institutions have $8.62M invested in Opus Genetics in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more capital invested

Capital invested by funds: $5.61M → $8.62M (+$3.02M)

50% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 6

1.43% more ownership

Funds ownership: 8.51% → 9.94% (+1.4%)

6% more call options, than puts

Call options by funds: $701K | Put options by funds: $664K

17% less funds holding

Funds holding: 36 → 30 (-6)

50% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 12

Holders
30
Holders Change
-6
Holders Change %
-16.67%
% of All Funds
0.53%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
9
Reduced
6
Closed
12
Calls
$701K
Puts
$664K
Net Calls
+$37K
Net Calls Change
+$51K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$4.35M
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$246K
3
Two Sigma Advisers
Two Sigma Advisers
New York
+$202K
4
Citadel Advisors
Citadel Advisors
Florida
+$199K
5
Two Sigma Investments
Two Sigma Investments
New York
+$170K

Top Sellers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
-$1.74M
2
NPF
Norris Perne & French
Michigan
-$417K
3
Goldman Sachs
Goldman Sachs
New York
-$197K
4
Renaissance Technologies
Renaissance Technologies
New York
-$188K
5
State Street
State Street
Massachusetts
-$183K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$5.05M +$4.35M +943,591 +2,540%
IC
2
Ikarian Capital
Texas
$608K -$6.86K -1,488 -1%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$406K +$246K +53,329 +208%
Citadel Advisors
4
Citadel Advisors
Florida
$296K +$199K +43,245 +303%
Two Sigma Advisers
5
Two Sigma Advisers
New York
$226K +$202K +43,900 New
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$210K -$84.7K -18,378 -31%
Two Sigma Investments
7
Two Sigma Investments
New York
$190K +$170K +36,883 New
BlackRock
8
BlackRock
New York
$175K -$2.37K -514 -1%
Group One Trading
9
Group One Trading
Illinois
$163K +$53.7K +11,656 +58%
Millennium Management
10
Millennium Management
New York
$136K +$122K +26,427 New
FWM
11
Frontier Wealth Management
Missouri
$129K +$115K +25,000 New
Comerica Bank
12
Comerica Bank
Texas
$127K – – –
OQS
13
Occudo Quantitative Strategies
Florida
$112K -$7.96K -1,726 -7%
LPL Financial
14
LPL Financial
California
$103K +$92.3K +20,024 New
Morgan Stanley
15
Morgan Stanley
New York
$99K +$25.4K +5,500 +40%
SFI
16
Susquehanna Fundamental Investments
Pennsylvania
$98K +$12K +2,600 +16%
State Street
17
State Street
Massachusetts
$77K -$183K -39,600 -73%
RCM
18
Regency Capital Management
Hawaii
$77K – – –
SFO
19
Stokes Family Office
Louisiana
$62K – – –
Northern Trust
20
Northern Trust
Illinois
$62K +$55.9K +12,131 New
BFM
21
Boothbay Fund Management
New York
$61K -$6.86K -1,488 -11%
CC
22
Cornerstone Capital
California
$58K – – –
MA
23
MCF Advisors
Kentucky
$49K – – –
UBS Group
24
UBS Group
Switzerland
$41K +$10.6K +2,296 +41%
First Manhattan
25
First Manhattan
New York
$3K – – –
1
2

IRD Hedge Fund Activity: Q3 2021 in Review

30 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q3 2021, worth a combined $8.62M — up 54% from $5.61M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of IRD and 6 opened new positions — a net loss of 6 holders — while 6 trimmed existing stakes and 9 added.

The largest buyer was Vanguard Group, adding an estimated $4.35M. The largest seller was Marshall Wace, exiting entirely with an estimated $1.74M sold.

  • 30 institutional investors held Opus Genetics (IRD) as of Q3 2021, down from 36 in Q2 2021.
  • Funds reported $8.62M of Opus Genetics stock for Q3 2021, up 54% quarter-over-quarter.
  • 6 funds opened new Opus Genetics positions in Q3 2021 and 12 closed out, a net change of -6 holders.
  • The largest Opus Genetics buyer in Q3 2021 was Vanguard Group, an estimated $4.35M added.
  • The largest Opus Genetics seller in Q3 2021 was Marshall Wace, an estimated $1.74M sold.

Based on aggregated 13F filings for Q3 2021.